Peter Borchmann

9PUBLICATIONS
74CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunityHaematologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Aug 21, 2026
BrECADD in three days: Implementation of a condensed intensive first-line regimen in Hodgkin lymphoma.

|Nov 18, 2025
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.

Richard T Maziarz, Michael R Bishop, Constantine S Tam

|Jul 17, 2025
Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial.

Justin Ferdinandus, Helen Kaul, Alexander Fosså

|May 26, 2025
Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study.

Louise Marie Cremer, Ullrich Bethe, Peter Borchmann

|Sep 30, 2024
Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma.

Jan-Michel Heger, Laman Mammadova, Julia Mattlener

|Dec 12, 2022
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial.

Paul J Bröckelmann, Ina Bühnen, Julia Meissner

Pageof 2

Frequent Collaborators

5 joint publications

Paul Jan Bröckelmann

4 joint publications

Michael Fuchs

4 joint publications

Bastian von Tresckow

3 joint publications

Janina Jablonski